Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
NCT ID: NCT04019470
Last Updated: 2024-02-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
OBSERVATIONAL
2019-02-01
2022-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tomotherapy as Primary Radiotherapy for Multipule Brain Metastases
NCT04178330
Sequence of Radiation and Targeted Therapy in Brain Metastases
NCT04832672
Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme
NCT01464177
Proton and Heavy Ion Beam Radiation vs. Photon Beam Radiation for Newly Diagnosed Glioblastoma.
NCT04536649
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
NCT00058370
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* To be diagnosed with malignant brain tumors
* To eligible for radiation therapy
* Karnofsky performance status ≥ 70
* No prior radiation exposure
* Informed consent signed for blood sample collection and used for research purpose
Exclusion Criteria
* Patients who had no histological diagnosis
* Patients who do not wish to participate
* Patients with infections
3 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Capital Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jun Ren MD, PhD
Cancer Center Director
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Shijitan Hospital Cancer Center
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRPBT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.